Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide plus Adriamycin and Dexamethasone with high-dose Melphalan in previously untreated multiple myeloma
NL-OMON27202Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Nov 2001; status: active, not recruiting.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON27202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27202.